Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by BORIS SEPESI and STEPHEN G SWISHER.
BORIS SEPESI
Connection Strength
10.977
STEPHEN G SWISHER
  1. Role of neoadjuvant chemoimmunotherapy for resectable NSCLC. Nat Rev Clin Oncol. 2022 08; 19(8):497-498.
    View in: PubMed
    Score: 0.851
  2. Stage I lung cancer-to operate or to radiate? that is the question. J Thorac Dis. 2016 Sep; 8(9):2324-2327.
    View in: PubMed
    Score: 0.565
  3. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.
    View in: PubMed
    Score: 0.222
  4. Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. JTO Clin Res Rep. 2022 Nov; 3(11):100420.
    View in: PubMed
    Score: 0.215
  5. High-Risk Features of Esophageal Adenocarcinoma Following Neoadjuvant Chemoradiation: Patients for Whom Surgery Should Not Be Delayed. Ann Surg. 2023 05 01; 277(5):721-726.
    View in: PubMed
    Score: 0.214
  6. Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.
    View in: PubMed
    Score: 0.205
  7. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection. Lung Cancer. 2022 02; 164:69-75.
    View in: PubMed
    Score: 0.205
  8. Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun. 2021 08 19; 12(1):5045.
    View in: PubMed
    Score: 0.199
  9. Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Ann Thorac Surg. 2022 01; 113(1):200-208.
    View in: PubMed
    Score: 0.195
  10. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy. J Thorac Oncol. 2021 08; 16(8):1289-1297.
    View in: PubMed
    Score: 0.195
  11. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.
    View in: PubMed
    Score: 0.193
  12. Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment. Lung Cancer. 2021 04; 154:76-83.
    View in: PubMed
    Score: 0.192
  13. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy. Eur J Cardiothorac Surg. 2021 01 04; 59(1):100-108.
    View in: PubMed
    Score: 0.191
  14. Peripheral cytokines are not influenced by the type of surgical approach for non-small cell lung cancer by four weeks postoperatively. Lung Cancer. 2020 08; 146:303-309.
    View in: PubMed
    Score: 0.184
  15. Time trends and predictors of survival in surgically resected early-stage non-small cell lung cancer patients. J Surg Oncol. 2020 Sep; 122(3):495-505.
    View in: PubMed
    Score: 0.182
  16. Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort. J Immunother Cancer. 2020 04; 8(1).
    View in: PubMed
    Score: 0.181
  17. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy. Clin Lung Cancer. 2020 07; 21(4):341-348.
    View in: PubMed
    Score: 0.180
  18. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020 07; 21(4):e294-e301.
    View in: PubMed
    Score: 0.179
  19. Lymphovascular Invasion Is Associated With Mutational Burden and PD-L1 in Resected Lung Cancer. Ann Thorac Surg. 2020 02; 109(2):358-366.
    View in: PubMed
    Score: 0.175
  20. Time Trends of Perioperative Outcomes in Early Stage Non-Small Cell Lung Cancer Resection Patients. Ann Thorac Surg. 2020 02; 109(2):404-411.
    View in: PubMed
    Score: 0.174
  21. Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database. J Thorac Dis. 2019 Apr; 11(4):1269-1278.
    View in: PubMed
    Score: 0.169
  22. Predictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution series. J Surg Oncol. 2018 Sep; 118(3):518-524.
    View in: PubMed
    Score: 0.162
  23. Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2018 05 01; 53(5):960-966.
    View in: PubMed
    Score: 0.159
  24. Prognostic Value of PD-L1 mRNA Sequencing Expression Profile in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 06; 105(6):1621-1626.
    View in: PubMed
    Score: 0.157
  25. Genetic variants in cytokine signaling pathways and clinical outcomes in early-stage lung cancer patients. J Thorac Cardiovasc Surg. 2018 06; 155(6):2635-2645.e15.
    View in: PubMed
    Score: 0.156
  26. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3354-3362.
    View in: PubMed
    Score: 0.151
  27. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer. Semin Thorac Cardiovasc Surg. 2017 Autumn; 29(3):408-415.
    View in: PubMed
    Score: 0.149
  28. The Influence of Reconstructive Technique on Perioperative Pulmonary and Infectious Outcomes Following Chest Wall Resection. Ann Thorac Surg. 2016 Nov; 102(5):1653-1659.
    View in: PubMed
    Score: 0.141
  29. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Ann Thorac Surg. 2016 Mar; 101(3):1075-80; Discussion 1080-1.
    View in: PubMed
    Score: 0.134
  30. The influence of histopathologic tumor viability on long-term survival and recurrence rates following neoadjuvant therapy for esophageal adenocarcinoma. Ann Surg. 2013 Sep; 258(3):500-7.
    View in: PubMed
    Score: 0.115
  31. Omental reinforcement of the thoracic esophagogastric anastomosis: an analysis of leak and reintervention rates in patients undergoing planned and salvage esophagectomy. J Thorac Cardiovasc Surg. 2012 Nov; 144(5):1146-50.
    View in: PubMed
    Score: 0.107
  32. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. J Immunother Cancer. 2024 Oct 23; 12(10).
    View in: PubMed
    Score: 0.062
  33. Octreotide's role in the management of post-esophagectomy chylothorax. Dis Esophagus. 2024 Jun 01; 37(6).
    View in: PubMed
    Score: 0.060
  34. Early Interventional Treatment of High Output Chyle Leak After Esophagectomy is Associated With Improved Survival. Ann Surg. 2024 Jul 01; 280(1):91-97.
    View in: PubMed
    Score: 0.060
  35. Chemotherapy Plus Atezolizumab Pre- and Post-Resection in Localized Esophageal or Gastroesophageal Junction Adenocarcinomas: A Phase I/II Single-Arm Study. Cancers (Basel). 2024 Mar 31; 16(7).
    View in: PubMed
    Score: 0.060
  36. Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer. Ann Oncol. 2024 Feb; 35(2):183-189.
    View in: PubMed
    Score: 0.058
  37. Do resected colorectal cancer patients need early chest imaging? Impact of clinicopathologic characteristics on time to development of pulmonary metastases. J Surg Oncol. 2024 Feb; 129(2):331-337.
    View in: PubMed
    Score: 0.058
  38. Circulomic variables predict pathologic staging preoperatively in treatment-na?ve non-small cell lung cancer. J Thorac Dis. 2023 Oct 31; 15(10):5507-5516.
    View in: PubMed
    Score: 0.058
  39. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy. Mod Pathol. 2024 Jan; 37(1):100353.
    View in: PubMed
    Score: 0.058
  40. Surgical outcomes after chemotherapy plus nivolumab and chemotherapy plus nivolumab and ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 Apr; 167(4):1444-1453.e4.
    View in: PubMed
    Score: 0.058
  41. Impact of travel distance on receipt of indicated adjuvant therapy in resected non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024 May; 167(5):1617-1627.
    View in: PubMed
    Score: 0.057
  42. Perioperative and oncologic outcomes of pulmonary resection for synchronous oligometastatic non-small cell lung cancer: Evidence for surgery in advanced disease. J Thorac Cardiovasc Surg. 2024 Jun; 167(6):1929-1935.e2.
    View in: PubMed
    Score: 0.057
  43. Lung surveillance following colorectal cancer pulmonary metastasectomy: Utilization of clinicopathologic risk factors to guide strategy. J Thorac Cardiovasc Surg. 2024 Mar; 167(3):814-819.e2.
    View in: PubMed
    Score: 0.057
  44. Perspectives, risk factors, and coping mechanisms in patients with self-reported financial burden following lung cancer surgery. J Thorac Cardiovasc Surg. 2024 02; 167(2):478-487.e2.
    View in: PubMed
    Score: 0.057
  45. Financial Toxicity in Patients With Resected Lung Cancer. Ann Surg. 2023 12 01; 278(6):1038-1044.
    View in: PubMed
    Score: 0.056
  46. Disparities in early-stage lung cancer outcomes at minority-serving hospitals compared with nonminority serving hospitals. J Thorac Cardiovasc Surg. 2024 01; 167(1):329-337.e4.
    View in: PubMed
    Score: 0.056
  47. Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Ann Thorac Surg. 2024 Feb; 117(2):320-326.
    View in: PubMed
    Score: 0.056
  48. Surgical Approach and Persistent Opioid Use in Medicare Patients Undergoing Lung Cancer Resection. Ann Thorac Surg. 2023 Nov; 116(5):1020-1027.
    View in: PubMed
    Score: 0.055
  49. Analysis of Immune Intratumor Heterogeneity Highlights Immunoregulatory and Coinhibitory Lymphocytes as Hallmarks of?Recurrence in Stage I Non-Small Cell Lung Cancer. Mod Pathol. 2023 01; 36(1):100028.
    View in: PubMed
    Score: 0.055
  50. Clinical outcomes of combined cervical and transthoracic surgical approaches in patients with advanced thyroid cancer. Head Neck. 2023 03; 45(3):547-554.
    View in: PubMed
    Score: 0.055
  51. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov. 2022 11 02; 12(11):2626-2645.
    View in: PubMed
    Score: 0.054
  52. Intraoperative challenges after induction therapy for non-small cell lung cancer: Effect of nodal disease on technical complexity. JTCVS Open. 2022 Dec; 12:372-384.
    View in: PubMed
    Score: 0.054
  53. Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment. Lung Cancer. 2022 10; 172:19-28.
    View in: PubMed
    Score: 0.053
  54. Repeated Pulmonary Metastasectomy: Third?Operations and Beyond. Ann Thorac Surg. 2023 03; 115(3):679-685.
    View in: PubMed
    Score: 0.053
  55. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. Clin Cancer Res. 2022 06 01; 28(11):2461-2473.
    View in: PubMed
    Score: 0.053
  56. The Role of Surgery in the Treatment of Melanoma Pulmonary Metastases in the Modern Era. J Surg Res. 2022 09; 277:125-130.
    View in: PubMed
    Score: 0.052
  57. Prolonged neutrophilia is associated with worse outcomes after Esophagectomy. Dis Esophagus. 2022 Apr 19; 35(4).
    View in: PubMed
    Score: 0.052
  58. Surgical Complexity of Pulmonary Resections Performed for Oligometastatic NSCLC. JTO Clin Res Rep. 2022 Mar; 3(3):100288.
    View in: PubMed
    Score: 0.051
  59. Single Chest Drain Practice Reduces Discharge Opioid Prescriptions in Thoracic Surgery. Thorac Cardiovasc Surg. 2022 08; 70(5):422-429.
    View in: PubMed
    Score: 0.051
  60. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun. 2021 12 06; 12(1):7081.
    View in: PubMed
    Score: 0.051
  61. Salvage Esophagectomy Definition Influences Comparative Outcomes in Esophageal Squamous Cell Cancers. Ann Thorac Surg. 2022 12; 114(6):2032-2040.
    View in: PubMed
    Score: 0.051
  62. Barriers to surveillance imaging adherence in early-staged lung cancer. J Thorac Dis. 2021 Dec; 13(12):6848-6854.
    View in: PubMed
    Score: 0.051
  63. Matched Pairs Comparison of an Enhanced Recovery Pathway Versus Conventional Management on Opioid Exposure and Pain Control in Patients Undergoing Lung Surgery. Ann Surg. 2021 12 01; 274(6):1099-1106.
    View in: PubMed
    Score: 0.051
  64. Sustained reduction of discharge opioid prescriptions in an enhanced recovery after thoracic surgery program: A multilevel generalized linear model. Surgery. 2022 02; 171(2):504-510.
    View in: PubMed
    Score: 0.051
  65. Analysis of trimodal and bimodal therapy in a selective-surgery paradigm for locally advanced oesophageal squamous cell carcinoma. Br J Surg. 2021 10 23; 108(10):1207-1215.
    View in: PubMed
    Score: 0.050
  66. Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small-cell lung cancer. Ann Oncol. 2022 01; 33(1):42-56.
    View in: PubMed
    Score: 0.050
  67. Clinical Significance of [18F] Fluoro-2-Deoxy-d-Glucose/Computed Tomographic Avid Hilar Lymph Nodes in Esophageal Carcinoma Patients. Ann Thorac Surg. 2022 10; 114(4):1183-1188.
    View in: PubMed
    Score: 0.050
  68. Optimizing Discharge After Shorter Hospitalizations: Lessons Learned Through After-Hours Calls with Thoracic Surgical Patients. Innovations (Phila). 2021 Nov-Dec; 16(6):529-535.
    View in: PubMed
    Score: 0.050
  69. Modern Perioperative Practices May Mitigate Effects of Continued Smoking Among Lung Cancer Patients. Ann Thorac Surg. 2022 07; 114(1):286-292.
    View in: PubMed
    Score: 0.050
  70. Preoperative Maximum Standardized Uptake Value Associated With Recurrence Risk in Early Lung Cancer. Ann Thorac Surg. 2022 06; 113(6):1835-1844.
    View in: PubMed
    Score: 0.049
  71. Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility. J Surg Oncol. 2021 Sep; 124(4):699-703.
    View in: PubMed
    Score: 0.049
  72. Robotic Surgery and Anatomic Segmentectomy: An Analysis of Trends, Patient Selection, and Outcomes. Ann Thorac Surg. 2022 03; 113(3):975-983.
    View in: PubMed
    Score: 0.049
  73. Impact of Psychiatric Comorbidities on Surgical Outcomes for Non-Small Cell Lung?Cancer. Ann Thorac Surg. 2022 03; 113(3):1008-1014.
    View in: PubMed
    Score: 0.048
  74. Intestinal Metaplasia in the Esophageal Remnant Is Rare After Ivor Lewis Esophagectomy. J Gastrointest Surg. 2021 09; 25(9):2185-2191.
    View in: PubMed
    Score: 0.048
  75. Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. J Thorac Oncol. 2021 04; 16(4):583-600.
    View in: PubMed
    Score: 0.048
  76. Liposomal Bupivacaine Intercostal Block Is Important for Reduction of Pulmonary Complications. Ann Thorac Surg. 2021 08; 112(2):423-429.
    View in: PubMed
    Score: 0.047
  77. Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. J Thorac Oncol. 2021 01; 16(1):127-139.
    View in: PubMed
    Score: 0.047
  78. Postoperative Bleeding and Acute Kidney Injury in Esophageal Cancer Patients Receiving Ketorolac. Ann Thorac Surg. 2021 04; 111(4):1111-1117.
    View in: PubMed
    Score: 0.047
  79. Esophageal adenocarcinoma with any component of signet ring cells portends poor prognosis and response to neoadjuvant therapy. J Thorac Cardiovasc Surg. 2021 Nov; 162(5):1404-1412.e2.
    View in: PubMed
    Score: 0.047
  80. Modified En Bloc Esophagectomy Compared With Standard Resection After Neoadjuvant Chemoradiation. Ann Thorac Surg. 2021 04; 111(4):1133-1140.
    View in: PubMed
    Score: 0.047
  81. Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res. 2020 10 15; 26(20):5477-5486.
    View in: PubMed
    Score: 0.046
  82. Importance of resection for locoregional disease control in Masaoka stage IVA thymic neoplasms. J Surg Oncol. 2020 Sep; 122(3):515-522.
    View in: PubMed
    Score: 0.046
  83. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.
    View in: PubMed
    Score: 0.046
  84. Genomic assessment distinguishes intrapulmonary metastases from synchronous primary lung cancers. J Thorac Dis. 2020 May; 12(5):1952-1959.
    View in: PubMed
    Score: 0.046
  85. 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020 Aug; 69(8):1519-1534.
    View in: PubMed
    Score: 0.045
  86. A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.
    View in: PubMed
    Score: 0.045
  87. Morbidity following salvage esophagectomy for squamous cell carcinoma: the MD Anderson experience. Dis Esophagus. 2020 Mar 16; 33(3).
    View in: PubMed
    Score: 0.045
  88. Hospital readmissions after pulmonary resection: post-discharge nursing telephone assessment identifies high risk patients. J Thorac Dis. 2020 Mar; 12(3):184-190.
    View in: PubMed
    Score: 0.045
  89. Immune regulatory markers of lepidic-pattern adenocarcinomas presenting as ground glass opacities. J Thorac Dis. 2020 Mar; 12(3):329-337.
    View in: PubMed
    Score: 0.045
  90. High mutational concordance between primary colorectal tumors and associated pulmonary metastases. J Surg Oncol. 2020 May; 121(6):984-989.
    View in: PubMed
    Score: 0.045
  91. Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nat Commun. 2020 01 30; 11(1):603.
    View in: PubMed
    Score: 0.045
  92. Surveillance After Treatment of Non-Small-Cell Lung Cancer: A Call for Multidisciplinary Standardization. Innovations (Phila). 2020 Jan/Feb; 15(1):57-65.
    View in: PubMed
    Score: 0.044
  93. Preoperative Heparin for Lung Cancer Resection Increases Risk of Reoperation for Bleeding. Semin Thorac Cardiovasc Surg. 2020 Summer; 32(2):337-343.
    View in: PubMed
    Score: 0.044
  94. Should endoscopic mucosal resection be attempted for cT2N0 esophageal cancer? Dis Esophagus. 2019 Dec 13; 32(10):1-6.
    View in: PubMed
    Score: 0.044
  95. Improved Overall Survival With Comprehensive Local Consolidative Therapy in Synchronous Oligometastatic Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2020 01; 21(1):37-46.e7.
    View in: PubMed
    Score: 0.043
  96. Multidisciplinary treatment of thymic neuroendocrine tumors: surgery remains a key component. J Thorac Dis. 2019 Aug; 11(8):3391-3398.
    View in: PubMed
    Score: 0.043
  97. Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice. Cancer. 2019 11 01; 125(21):3738-3748.
    View in: PubMed
    Score: 0.043
  98. Colorectal cancer mutations are associated with survival and recurrence after pulmonary metastasectomy. J Surg Oncol. 2019 Sep; 120(4):729-735.
    View in: PubMed
    Score: 0.043
  99. Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization. Am J Cancer Res. 2019; 9(6):1201-1211.
    View in: PubMed
    Score: 0.043
  100. Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma. Ann Thorac Surg. 2019 09; 108(3):845-851.
    View in: PubMed
    Score: 0.043
  101. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565.
    View in: PubMed
    Score: 0.043
  102. Robotic-Assisted Lobectomy for Non-Small Cell Lung Cancer: A Comprehensive Institutional Experience. Ann Thorac Surg. 2019 08; 108(2):370-376.
    View in: PubMed
    Score: 0.042
  103. Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases. J Thorac Cardiovasc Surg. 2019 04; 157(4):1648-1655.
    View in: PubMed
    Score: 0.041
  104. Ground Glass Lesions on Chest Imaging: Evaluation of Reported Incidence in Cancer Patients Using Natural Language Processing. Ann Thorac Surg. 2019 03; 107(3):936-940.
    View in: PubMed
    Score: 0.041
  105. Multimodality Therapy for N2 Non-Small Cell Lung Cancer: An Evolving Paradigm. Ann Thorac Surg. 2019 01; 107(1):277-284.
    View in: PubMed
    Score: 0.041
  106. Perioperative Outcomes for Stage I Non-Small Cell Lung Cancer: Differences Between Men and Women. Ann Thorac Surg. 2018 11; 106(5):1499-1503.
    View in: PubMed
    Score: 0.040
  107. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. J Immunother Cancer. 2018 06 06; 6(1):48.
    View in: PubMed
    Score: 0.040
  108. Clinicoradiographic Predictors of Aggressive Biology in Lung Cancer With Ground Glass Components. Ann Thorac Surg. 2018 07; 106(1):235-241.
    View in: PubMed
    Score: 0.039
  109. Enhanced Recovery Decreases Pulmonary and Cardiac Complications After Thoracotomy for Lung Cancer. Ann Thorac Surg. 2018 07; 106(1):272-279.
    View in: PubMed
    Score: 0.039
  110. Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors. J Thorac Oncol. 2018 06; 13(6):779-791.
    View in: PubMed
    Score: 0.039
  111. Natural History of Ground-Glass Lesions Among Patients With Previous Lung Cancer. Ann Thorac Surg. 2018 06; 105(6):1671-1677.
    View in: PubMed
    Score: 0.039
  112. Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2018 Feb; 105(2):418-424.
    View in: PubMed
    Score: 0.039
  113. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing. Cancer. 2018 03 01; 124(5):1061-1069.
    View in: PubMed
    Score: 0.038
  114. Perioperative Outcomes of Patients Undergoing Lobectomy on Clopidogrel. Ann Thorac Surg. 2017 Dec; 104(6):1821-1828.
    View in: PubMed
    Score: 0.038
  115. Pathological complete response in patients with esophageal cancer after the trimodality approach: The association with baseline variables and survival-The University of Texas MD Anderson Cancer Center experience. Cancer. 2017 Nov 01; 123(21):4106-4113.
    View in: PubMed
    Score: 0.038
  116. TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. Cancer Discov. 2017 10; 7(10):1088-1097.
    View in: PubMed
    Score: 0.038
  117. Salvage pulmonary resection after stereotactic body radiotherapy: A feasible and safe option for local failure in selected patients. J Thorac Cardiovasc Surg. 2017 08; 154(2):689-699.
    View in: PubMed
    Score: 0.037
  118. Polytetrafluoroethylene or Acellular Dermal Matrix for Diaphragmatic Reconstruction? Ann Thorac Surg. 2017 Jun; 103(6):1710-1714.
    View in: PubMed
    Score: 0.037
  119. Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells. Cancer Immunol Res. 2017 04; 5(4):319-329.
    View in: PubMed
    Score: 0.037
  120. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682.
    View in: PubMed
    Score: 0.036
  121. Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients. Clin Cancer Res. 2016 Dec 15; 22(24):6278-6289.
    View in: PubMed
    Score: 0.035
  122. Results of Postdischarge Nursing Telephone Assessments: Persistent Symptoms Common Among Pulmonary Resection Patients. Ann Thorac Surg. 2016 Jul; 102(1):276-81.
    View in: PubMed
    Score: 0.034
  123. SABR vs surgery for NSCLC in the media. Lancet Oncol. 2015 Sep; 16(9):e422.
    View in: PubMed
    Score: 0.033
  124. Clinical Prediction of Pathologic Complete Response in Superior Sulcus Non-Small Cell Lung Cancer. Ann Thorac Surg. 2016 Jan; 101(1):211-7.
    View in: PubMed
    Score: 0.033
  125. Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer. Cancer Lett. 2015 Feb 01; 357(1):179-185.
    View in: PubMed
    Score: 0.031
  126. A clinical nomogram predicting pathologic lymph node involvement in esophageal cancer patients. Ann Surg. 2010 Oct; 252(4):611-7.
    View in: PubMed
    Score: 0.023
  127. Endoscopic esophageal tumor length: a prognostic factor for patients with esophageal cancer. Cancer. 2011 Jan 01; 117(1):63-9.
    View in: PubMed
    Score: 0.023
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.